Abstract #2917

Providing improved reliability of plasma volume fraction estimates for monitoring anti-angiogenic effects in liver metastases with DCE-MRI

Mihaela Rata¹, Khurum Khan¹, David Collins¹, Nina Tunariu¹, Dow-Mu Koh¹, James d'Arcy¹, Maria Bali¹, Ian Chau¹, Nicola Valeri¹, David Cunningham¹, Martin O Leach¹, and Matthew Orton¹

¹CR-UK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom

Pharmacokinetic modelling of DCE-MRI data allows characterisation of tumour response to anti-angiogenic therapies by estimating the volume transfer constant K^trans and the plasma volume fraction Vp. This work assesses the impact on K^trans and Vp of treatment changes in an early clinical trial cohort by comparing 4 models: Kety, extended Kety (with two lower limits on Vp), and a new model with Vp proportional to K^trans. When K^trans is the endpoint of interest, use of the Kety model is sufficient to depict cohort response. If Vp is also of interest, the new model improves the significance of Vp treatment effects.

This abstract and the presentation materials are available to members only; a login is required.

Join Here